In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey

Margo Olbrecht, Fedoua Echahidi, Denis Piérard, Charlotte Peeters, Peter Vandamme, Ingrid Wybo, Thomas Demuyser

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We conducted in vitro antimicrobial susceptibility testing of 267 Achromobacter isolates for 16 antibiotics from 2017 to 2022. The highest susceptibility was found for piperacillin-tazobactam (70%) and ceftazidime-avibactam (62%). Between 30% and 49% of strains were susceptible to tigecycline, ceftazidime, and meropenem. We applied species-specific Achromobacter xylosoxidans breakpoints for piperacillin-tazobactam, meropenem, and trimethoprim-sulfamethoxazole and EUCAST pharmacokinetic/pharmacodynamic (PK/PD) breakpoints for the others. A. xylosoxidans was the most frequently isolated species, followed by Achromobacter insuavis and Achromobacter ruhlandii.

Original languageEnglish
Article numbere0037923
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume67
Issue number7
DOIs
Publication statusPublished - 18 Jul 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 American Society for Microbiology.

Keywords

  • Achromobacter
  • In vitro susceptibility
  • antibiotic resistance
  • cystic fibrosis

Fingerprint

Dive into the research topics of 'In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey'. Together they form a unique fingerprint.

Cite this